Last Updated: November 18, 2026

PLUVICTO Drug Patent Profile

« Back to Dashboard


When do Pluvicto patents expire, and when can generic versions of Pluvicto launch?

Pluvicto is a drug marketed by Novartis and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in PLUVICTO is lutetium lu-177 vipivotide tetraxetan. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu-177 vipivotide tetraxetan profile page.

DrugPatentWatch® Generic Entry Outlook for Pluvicto

Pluvicto was eligible for patent challenges on March 23, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for PLUVICTO?
  • What are the global sales for PLUVICTO?
  • What is Average Wholesale Price for PLUVICTO?
Summary for PLUVICTO
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 9
Patent Applications: 234
Drug Prices: Drug price information for PLUVICTO
What excipients (inactive ingredients) are in PLUVICTO?PLUVICTO excipients list
DailyMed Link:PLUVICTO at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PLUVICTO
Generic Entry Date for PLUVICTO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PLUVICTO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterNA
GE HealthcareNA
Canadian Institutes of Health Research (CIHR)PHASE1

See all PLUVICTO clinical trials

Pharmacology for PLUVICTO

US Patents and Regulatory Information for PLUVICTO

PLUVICTO is protected by thirteen US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PLUVICTO is ⤷  Start Trial.

This potential generic entry date is based on patent 10,398,791.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 12,208,102 ⤷  Start Trial ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 10,406,240 ⤷  Start Trial Y Y ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novartis PLUVICTO lutetium lu-177 vipivotide tetraxetan SOLUTION;INTRAVENOUS 215833-001 Mar 23, 2022 RX Yes Yes 11,951,190 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PLUVICTO

When does loss-of-exclusivity occur for PLUVICTO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14336638
Estimated Expiration: ⤷  Start Trial

Patent: 18200419
Estimated Expiration: ⤷  Start Trial

Patent: 20201086
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 24360
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 16000883
Estimated Expiration: ⤷  Start Trial

China

Patent: 5636924
Estimated Expiration: ⤷  Start Trial

Patent: 9053616
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0240398
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 26819
Estimated Expiration: ⤷  Start Trial

Patent: 24023
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 7778
Estimated Expiration: ⤷  Start Trial

Patent: 1690495
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 62857
Estimated Expiration: ⤷  Start Trial

Patent: 38996
Estimated Expiration: ⤷  Start Trial

Patent: 15489
Estimated Expiration: ⤷  Start Trial

Patent: 56700
Estimated Expiration: ⤷  Start Trial

Patent: 95355
Estimated Expiration: ⤷  Start Trial

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Patent: 74924
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Patent: 0240024
Estimated Expiration: ⤷  Start Trial

France

Patent: C1028
Estimated Expiration: ⤷  Start Trial

Georgia, Republic of

Patent: 202114132
Estimated Expiration: ⤷  Start Trial

Patent: 202215377
Estimated Expiration: ⤷  Start Trial

Patent: 202215719
Estimated Expiration: ⤷  Start Trial

Patent: 202215720
Estimated Expiration: ⤷  Start Trial

Patent: 0217330
Estimated Expiration: ⤷  Start Trial

Patent: 0237479
Estimated Expiration: ⤷  Start Trial

Patent: 0237496
Estimated Expiration: ⤷  Start Trial

Patent: 0237497
Estimated Expiration: ⤷  Start Trial

Germany

Patent: 2014011593
Estimated Expiration: ⤷  Start Trial

Patent: 2014011600
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 21711
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 66137
Estimated Expiration: ⤷  Start Trial

Patent: 400024
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 5113
Estimated Expiration: ⤷  Start Trial

Patent: 8974
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 56805
Estimated Expiration: ⤷  Start Trial

Patent: 01451
Estimated Expiration: ⤷  Start Trial

Patent: 36774
Estimated Expiration: ⤷  Start Trial

Patent: 94161
Estimated Expiration: ⤷  Start Trial

Patent: 93485
Estimated Expiration: ⤷  Start Trial

Patent: 27675
Estimated Expiration: ⤷  Start Trial

Patent: 16535013
Estimated Expiration: ⤷  Start Trial

Patent: 18058847
Estimated Expiration: ⤷  Start Trial

Patent: 19011368
Estimated Expiration: ⤷  Start Trial

Patent: 19218351
Estimated Expiration: ⤷  Start Trial

Patent: 21059557
Estimated Expiration: ⤷  Start Trial

Patent: 22159345
Estimated Expiration: ⤷  Start Trial

Patent: 24028742
Estimated Expiration: ⤷  Start Trial

Patent: 26119201
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Patent: 2024522
Estimated Expiration: ⤷  Start Trial

Luxembourg

Patent: 0352
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 8934
Estimated Expiration: ⤷  Start Trial

Patent: 4484
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 6634
Estimated Expiration: ⤷  Start Trial

Patent: 6635
Estimated Expiration: ⤷  Start Trial

Patent: 16005013
Estimated Expiration: ⤷  Start Trial

Patent: 21008976
Estimated Expiration: ⤷  Start Trial

Patent: 21008977
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 986
Estimated Expiration: ⤷  Start Trial

Netherlands

Patent: 1281
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 8812
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 160678
Estimated Expiration: ⤷  Start Trial

Patent: 211760
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 016500656
Estimated Expiration: ⤷  Start Trial

Patent: 019502571
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 95130
Estimated Expiration: ⤷  Start Trial

Saudi Arabia

Patent: 6370842
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 324
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 201602249R
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 95130
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1603380
Estimated Expiration: ⤷  Start Trial

Patent: 1907607
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1947053
Estimated Expiration: ⤷  Start Trial

Patent: 2210931
Estimated Expiration: ⤷  Start Trial

Patent: 2282378
Estimated Expiration: ⤷  Start Trial

Patent: 160063398
Estimated Expiration: ⤷  Start Trial

Patent: 190016133
Estimated Expiration: ⤷  Start Trial

Patent: 210013350
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 77715
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 16000137
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PLUVICTO around the world.

Country Patent Number Title Estimated Expiration
Australia 2014336638 ⤷  Start Trial
Australia 2018200419 ⤷  Start Trial
Australia 2020201086 ⤷  Start Trial
Canada 2924360 ⤷  Start Trial
Chile 2016000883 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PLUVICTO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4095130 CA 2024 00027 Denmark ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130 LUC00352 Luxembourg ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130 301281 Netherlands ⤷  Start Trial PRODUCT NAME: LUTETIUM (177-LU)-VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703, 20221212
4095130 PA2024522 Lithuania ⤷  Start Trial PRODUCT NAME: LUTECIO (177LU) VIPIVOTIDO TETRAKSETANAS; REGISTRATION NO/DATE: EU/1/22/1703 20221209
4095130 2024C/528 Belgium ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Pluvicto Market Dynamics, Revenue Growth, Patent Risk, and Financial Trajectory

Last updated: November 10, 2026

Pluvicto is Novartis' lutetium-177 radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer, or mCRPC. Its commercial trajectory is driven by expanding treatment eligibility, growing PSMA-PET testing, manufacturing capacity, and adoption of radioligand therapy in community oncology. Novartis reported approximately $1.4 billion in Pluvicto sales in 2024, compared with $980 million in 2023 and $271 million in 2022.[1]

The principal near-term market catalyst is earlier-line use after androgen-receptor pathway inhibitor therapy and before taxane chemotherapy. The principal commercial constraints are radioligand manufacturing, isotope supply, specialized treatment centers, patient logistics, and competition from emerging PSMA-directed radiopharmaceuticals.

How large is the Pluvicto market?

Pluvicto addresses a large but specialized segment of advanced prostate cancer.

The FDA initially approved Pluvicto in March 2022 for adults with PSMA-positive mCRPC who had previously received androgen-receptor pathway inhibitor treatment and taxane-based chemotherapy.[2] The label expansion announced in March 2025 moved treatment earlier for eligible patients who had received an androgen-receptor pathway inhibitor and were appropriate candidates to delay taxane chemotherapy.[3]

Pluvicto revenue by year

Fiscal year Reported sales Approximate year-over-year growth Commercial status
2022 $271 million Not comparable Launch year
2023 $980 million 262% Initial global scale-up
2024 Approximately $1.4 billion Approximately 40% to 45% Broadening access and manufacturing expansion

Sources: Novartis annual reports and company financial disclosures.[1]

The 2022 figure reflected only part-year commercialization. The 2023 increase reflected wider reimbursement, greater physician familiarity, expansion of treatment sites, and increased PSMA-PET utilization. Growth moderated in 2024 as the product reached a larger revenue base, but remained strong for a specialty oncology product with complex delivery requirements.

When does Pluvicto lose exclusivity?

Pluvicto's commercial exclusivity is not determined by a single date.

The product is protected by a combination of composition-of-matter, radioligand, manufacturing, formulation, use, and potentially regulatory exclusivity rights. The relevant patent estate can include rights covering the PSMA-targeting ligand, chelator chemistry, radionuclide conjugation, pharmaceutical compositions, therapeutic dosing, patient selection, and production methods.

The exact generic-entry date depends on:

  1. The Orange Book-listed patents for NDA 215833.
  2. Any pediatric exclusivity attached to the product.
  3. Patent-term extension, if granted.
  4. Paragraph IV litigation.
  5. Whether a challenger can market an equivalent radiopharmaceutical under the ANDA pathway.
  6. Manufacturing and radioactive-material licensing requirements.

Pluvicto was approved in the United States under NDA 215833.[2] Its FDA-approved active ingredient is lutetium Lu 177 vipivotide tetraxetan. Unlike a conventional small-molecule tablet, the product requires controlled production, radiolabeling, quality release, transport, and administration at qualified nuclear medicine or oncology facilities.

What patents protect Pluvicto?

The commercial protection is likely strongest around the radioligand platform and manufacturing process rather than only the finished vial. Relevant protection categories include:

Protection category Commercial relevance
PSMA-targeting ligand Protects binding architecture and active targeting component
Chelator and linker chemistry Protects attachment of lutetium-177 to the targeting ligand
Radioligand composition Covers the active drug substance or pharmaceutical composition
Manufacturing and radiolabeling Raises technical barriers for competing products
Patient selection Protects treatment of PSMA-positive disease or defined prior-treatment populations
Dosing and administration May support method-of-use enforcement
Formulation and stability May protect injectable presentation and shelf-life characteristics

A conventional small-molecule generic may be difficult to commercialize even after a key composition patent expires because the competitor would need access to lutetium-177, validated radiolabeling infrastructure, quality systems, distribution logistics, and licensed administration sites.

What is the Orange Book status of Pluvicto?

Pluvicto is an FDA-approved prescription drug listed under NDA 215833. The Orange Book is relevant to any abbreviated new drug application, or ANDA, strategy, but the commercial assessment requires review of current FDA patent listings, certifications, litigation, and regulatory exclusivity.

The core business risk is different from that of a standard oral oncology product. An ANDA challenger would need to establish pharmaceutical equivalence and meet applicable radiopharmaceutical quality requirements. The product also has a short radioactive shelf life, specialized packaging, and strict controls over handling and transport.

No mature generic market exists for Pluvicto. The more credible competitive threat is likely to come first from other PSMA-targeted radioligand therapies rather than from a conventional generic version.

Which companies are challenging Pluvicto commercially?

The competitive field includes both direct PSMA radioligand programs and alternative radiopharmaceuticals.

Direct and adjacent competitors

Company Asset or product Competitive position
Novartis Pluvicto Commercial PSMA-targeted lutetium-177 therapy
Novartis Lutathera Established radioligand manufacturing and commercial infrastructure, but used in neuroendocrine tumors
Eli Lilly PNT2002 PSMA-targeted radioligand program obtained through Lilly's acquisition of Point Biopharma
Bristol Myers Squibb RYZ101 Actinium-225 targeted radiopharmaceutical program acquired through RayzeBio
Bayer Xofigo Approved alpha-particle radiopharmaceutical for bone-predominant mCRPC; does not target PSMA
Various biotechnology companies PSMA and other radioligand programs Earlier-stage competition using lutetium-177, actinium-225, or other isotopes

PNT2002 is the closest commercial competitor because it is also a PSMA-directed radioligand therapy. Actinium-225 programs may compete on isotope characteristics and disease setting, but they face separate supply, manufacturing, dosimetry, and clinical-development challenges.

How does Pluvicto compare with Xofigo and emerging PSMA radioligands?

Pluvicto has a broader biological targeting rationale than Xofigo because it binds PSMA-expressing tumor cells. Xofigo targets areas of increased bone turnover and is primarily relevant to symptomatic bone-metastatic disease without visceral metastases under its approved indication.[4]

Attribute Pluvicto Xofigo Emerging PSMA radioligands
Target PSMA Bone mineral at osteoblastic lesions Usually PSMA or another tumor antigen
Isotope Lutetium-177 Radium-223 Lutetium-177, actinium-225, or other isotopes
Disease focus PSMA-positive mCRPC Bone-metastatic mCRPC Depends on clinical program
Commercial status Approved and marketed Approved and marketed Mostly investigational
Delivery model Nuclear medicine or qualified radioligand center Nuclear medicine setting Requires specialized infrastructure
Key differentiation Tumor-targeted beta radiation Bone-targeted alpha radiation Potentially improved efficacy, safety, or dosing convenience

Pluvicto's commercial advantage is the combination of regulatory approval, clinical data, physician experience, production capacity, and an established PSMA-PET diagnostic pathway.

What is driving Pluvicto revenue growth?

Earlier-line treatment

Earlier use expands the addressable population. Patients treated before taxane chemotherapy represent a substantially larger segment than the initial post-taxane population. Earlier-line adoption also increases the potential number of treatment cycles per patient and improves the product's position in treatment sequencing.

The commercial outcome depends on the final label, physician treatment preferences, payer policies, and evidence regarding overall survival and quality of life. Novartis' Phase 3 PSMAfore study supported evaluation of Pluvicto after an androgen-receptor pathway inhibitor and before taxane chemotherapy.[5]

PSMA-PET adoption

Pluvicto requires confirmation of PSMA-positive disease using an approved imaging method. Greater use of PSMA-PET increases the number of patients identified as eligible for treatment. Imaging expansion also improves treatment selection and helps physicians integrate Pluvicto into routine prostate cancer pathways.

Treatment-center expansion

Radioligand therapy requires trained personnel, radiation-safety systems, infusion or administration capability, dosimetry procedures, and regulatory compliance. Expansion beyond academic hospitals is necessary to reach the broader mCRPC population.

Manufacturing scale

Novartis has invested in radioligand manufacturing and supply infrastructure. The company has identified manufacturing expansion as a central factor in meeting demand for Pluvicto and Lutathera.[1] Capacity additions can increase sales, but they also increase fixed costs and operational complexity.

What manufacturing and intellectual-property barriers affect Pluvicto?

Radiopharmaceutical manufacturing creates a barrier that is separate from patent protection.

A competing manufacturer needs:

  • Reliable lutetium-177 or alternative isotope supply.
  • GMP-compliant radiolabeling capability.
  • Validated release testing before shipment.
  • Radioactive-material licenses.
  • Specialized packaging and transport.
  • A network of qualified treatment centers.
  • Procedures for patient-specific scheduling and dose delivery.
  • Waste management and radiation-safety controls.

The isotope's half-life creates a time-sensitive supply chain. Delays in manufacturing, release testing, customs, transportation, or patient scheduling can reduce usable inventory. This favors companies with integrated isotope procurement and distribution networks.

Patent protection may prevent direct copying, but manufacturing barriers can delay competitive entry even when patent disputes are resolved. Conversely, manufacturing barriers do not eliminate litigation risk if a competitor develops a noninfringing radioligand or uses a different isotope.

What patent litigation and Paragraph IV risks affect Pluvicto?

A Paragraph IV challenge would be the primary U.S. pathway for an ANDA applicant asserting that a listed patent is invalid, unenforceable, or not infringed. The likely litigation issues would include:

  • Validity of the radioligand composition claims.
  • Written description and enablement of broad chemical-genus claims.
  • Obviousness of the ligand-chelator-radionuclide combination.
  • Scope of manufacturing claims.
  • Infringement by alternative radiolabeling processes.
  • Enforceability of method-of-use claims.
  • Whether the proposed product qualifies as pharmaceutically equivalent.

A direct generic challenge is less likely to define the near-term competitive landscape than branded radioligand competition. PNT2002 and actinium-225 programs could seek approval through full or hybrid development pathways rather than relying on an ANDA against Pluvicto.

No major publicly reported U.S. Pluvicto Paragraph IV settlement or final patent judgment is identified in the cited sources through the end of 2024. The 2025 label expansion creates additional method-of-use and market-access value, but it does not automatically create a new patent term.

What is the financial trajectory for Pluvicto?

The base-case trajectory is continued growth with a slower percentage rate after the 2024 scale-up.

Base-case commercial outlook

Period Expected dynamic
2022 Launch and constrained initial penetration
2023 Rapid adoption and international expansion
2024 Approximately $1.4 billion in sales; capacity and site expansion
2025-2026 Earlier-line uptake, broader treatment-center access, and increased PSMA-PET testing
Longer term Growth depends on label breadth, competitive radioligands, supply reliability, and payer adoption

Potential upside comes from earlier-line treatment, improved patient identification, expanded global reimbursement, and use in additional prostate cancer settings. Downside risks include manufacturing disruptions, isotope shortages, adverse safety signals, reimbursement restrictions, clinical competition, and treatment-center bottlenecks.

Pluvicto is strategically important to Novartis because it extends the company's oncology platform beyond conventional targeted therapies and strengthens its position in radioligand medicine. Revenue concentration remains meaningful: the product's success depends on a specialized supply chain and a limited number of qualified treatment sites.

What licensing deals support the Pluvicto market?

Pluvicto's commercial position reflects Novartis' acquisition and licensing history in radioligand therapy, including rights and technology associated with Advanced Accelerator Applications. Novartis acquired Advanced Accelerator Applications in 2018, obtaining Lutathera and the radioligand platform that supported later development of Pluvicto.[6]

The deal gave Novartis:

  • An established radioligand manufacturing platform.
  • Experience with nuclear medicine distribution.
  • Commercial relationships with treatment centers.
  • Technical expertise in isotope handling.
  • A foundation for expanding into PSMA-targeted oncology.

The competitive landscape has since shifted toward additional licensing and acquisitions. Lilly's acquisition of Point Biopharma and Bristol Myers Squibb's acquisition of RayzeBio show that large pharmaceutical companies view radioligand therapy as a strategic oncology category rather than a narrow niche.[7][8]

What generic launch scenarios exist for Pluvicto?

Three entry scenarios are commercially relevant.

Scenario 1: No direct generic before core protection expires

Novartis retains the market while competitors develop branded radioligands. Price erosion remains limited, but share shifts through clinical differentiation.

Scenario 2: ANDA challenge and delayed generic entry

A challenger files an ANDA with Paragraph IV certifications. Litigation delays launch, and a settlement establishes a later entry date. This is common for high-value specialty drugs but cannot be assumed for a complex radiopharmaceutical.

Scenario 3: Branded radioligand displacement

A competitor gains approval for a PSMA-targeted or alternative-isotope therapy. Market share declines without conventional generic substitution. Differentiation may be based on survival, safety, outpatient administration, dosing frequency, isotope supply, or treatment-center convenience.

The third scenario is the most relevant medium-term competitive risk.

How strong is the Pluvicto patent estate?

Pluvicto's protection is commercially strong because patent rights are reinforced by regulatory, manufacturing, and infrastructure barriers. The estate's durability depends on the remaining term of core composition patents, the breadth of issued claims, patent-term adjustments or extensions, and the enforceability of formulation and use claims.

Its strongest protection is likely concentrated in:

  1. The active radioligand architecture.
  2. The combination of PSMA ligand, linker, chelator, and lutetium-177.
  3. Manufacturing and radiolabeling methods.
  4. Patient-selection and treatment methods.
  5. Pharmaceutical formulation and stability.

The estate is less secure against a differentiated radioligand that uses a different ligand, linker, isotope, or manufacturing process. Such a product could compete clinically without infringing the central composition claims.

Key Takeaways

  • Pluvicto sales grew from $271 million in 2022 to $980 million in 2023 and approximately $1.4 billion in 2024.
  • Earlier-line treatment after androgen-receptor pathway inhibitor therapy is the largest market-expansion opportunity.
  • PSMA-PET adoption and treatment-center expansion directly affect patient volume.
  • Manufacturing capacity and isotope supply are major commercial barriers and operational risks.
  • The principal competitive threat is branded radioligand therapy, not a conventional generic.
  • PNT2002 and actinium-225 programs are the most relevant emerging competitive approaches.
  • Pluvicto's protection combines patents with regulatory exclusivity, radiopharmaceutical manufacturing complexity, and distribution infrastructure.
  • Generic-entry timing depends on current Orange Book listings, patent-term adjustments, pediatric exclusivity, Paragraph IV litigation, and settlement terms.
  • Novartis' radioligand platform and Advanced Accelerator Applications acquisition support long-term category leadership.
  • Revenue growth should continue if earlier-line adoption expands faster than competition and manufacturing constraints.

FAQs About Pluvicto Market Dynamics

What is Pluvicto's active ingredient?

Pluvicto contains lutetium Lu 177 vipivotide tetraxetan, a PSMA-targeted radioligand that delivers beta radiation to PSMA-expressing cancer cells.

Is Pluvicto a biologic or a generic drug?

Pluvicto is an FDA-approved radiopharmaceutical drug, not a conventional biologic. A future competitor could pursue an abbreviated or full approval route depending on product composition and regulatory comparability.

Why is Pluvicto difficult to manufacture?

Production requires radioactive isotope procurement, GMP radiolabeling, rapid release testing, specialized packaging, licensed transport, and coordinated delivery to qualified treatment centers.

Does Xofigo directly replace Pluvicto?

No. Xofigo is a radium-223 therapy directed toward bone-metastatic disease, while Pluvicto targets PSMA-expressing tumor cells. The products may compete in some prostate cancer treatment decisions but are not direct pharmaceutical equivalents.

What could reduce Pluvicto's future revenue?

The principal risks are earlier-than-expected branded radioligand competition, supply interruptions, isotope shortages, limited treatment-center capacity, payer restrictions, safety findings, weaker-than-expected earlier-line adoption, and patent challenges.

References

  1. Novartis AG. (2025). Annual report 2024. Novartis.
  2. U.S. Food and Drug Administration. (2022). FDA approves Pluvicto for metastatic castration-resistant prostate cancer. FDA.
  3. U.S. Food and Drug Administration. (2025). FDA expands Pluvicto indication for prostate cancer. FDA.
  4. U.S. Food and Drug Administration. (2018). FDA approves Xofigo for certain patients with prostate cancer. FDA.
  5. Novartis AG. (2023). Novartis announces positive Phase III PSMAfore results for Pluvicto. Novartis.
  6. Novartis AG. (2018). Novartis completes acquisition of Advanced Accelerator Applications. Novartis.
  7. Eli Lilly and Company. (2023). Lilly completes acquisition of Point Biopharma. Eli Lilly and Company.
  8. Bristol Myers Squibb. (2024). Bristol Myers Squibb completes acquisition of RayzeBio. Bristol Myers Squibb.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.